HIV合并HCV感染直接抗病毒治疗中肝内病毒动力学:ACTG A5335S亚研究
A5335S是A5329试验的亚研究,纳入5例HIV抑制的慢性1a型HCV合并感染者,接受paritaprevir/ritonavir、ombitasvir、dasabuvir联合利巴韦林治疗。第7天血浆HCV RNA平均下降4.1 log10 IU/mL,肝活检显示HCV感染肝细胞从25.2%降至1.0%(P<.05),推测63天可清除HCV但免疫激活可能持续。
要点
- DAA治疗第7天肝内HCV感染细胞从25.2%降至1.0%,血浆HCV RNA下降4.1 log10 IU/mL。
- 肝内HCV感染细胞比例与血浆HCV RNA强相关(r=0.9)。
- 推测63天可清除HCV,但免疫激活可能持续。
核心结论
- DAA治疗第7天肝内HCV感染细胞降至<2%,推测63天可清除HCV但免疫激活可能持续。
研究设计与样本
- A5335S是A5329试验的亚研究,纳入5例HIV抑制的慢性1a型HCV合并感染者,完成肝活检和血浆检测。
主要发现
- 基线血浆HCV RNA平均6.7 log10 IU/mL,第7天平均下降4.1 log10 IU/mL。
- 第一次肝活检平均HCV感染细胞比例25.2%(95%CI 7.4%-42.9%),与血浆HCV RNA强相关(r=0.9)。
- 第二次肝活检(第7天,5例中4例)平均HCV感染细胞比例1.0%(95%CI 0.2%-1.7%),变化P<.05,肝内可检测到DAA。
- 血浆CXCL10在24小时内平均每天下降160 pg/mL,第4天后无进一步变化。
临床怎么用
- 肝内HCV清除迅速,支持短疗程DAA治疗的可能性,但需考虑免疫激活持续。
局限性
- 样本量小(5例),部分参与者未完成第二次肝活检。
- extrapolation of eradication time based on limited data.
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct-acting antivirals (DAAs) targeting hepatitis C virus (HCV) have revolutionized outcomes in human immunodeficiency virus (HIV) coinfection. METHODS: We examined early events in liver and plasma through A5335S, a substudy of trial A5329 (paritaprevir/ritonavir, ombitasvir, dasabuvir, with ribavirin) that enrolled chronic genotype 1a HCV-infected persons coinfected with suppressed HIV: 5 of 6 treatment-naive enrollees completed A5335S. RESULTS: Mean baseline plasma HCV ribonucleic acid (RNA) = 6.7 log10 IU/mL and changed by -4.1 log10 IU/mL by Day 7. In liver, laser capture microdissection was used to quantify HCV. At liver biopsy 1, mean %HCV-infected cells = 25.2% (95% confidence interval [CI], 7.4%-42.9%), correlating with plasma HCV RNA (Spearman rank correlation r = 0.9); at biopsy 2 (Day 7 in 4 of 5 participants), mean %HCV-infected cells = 1.0% (95% CI, 0.2%-1.7%) (P < .05 for change), and DAAs were detectable in liver. Plasma C-X-C motif chemokine 10 (CXCL10) concentrations changed by mean = -160 pg/mL per day at 24 hours, but no further after Day 4. CONCLUSIONS: We conclude that HCV infection is rapidly cleared from liver with DAA leaving <2% HCV-infected hepatocytes at Day 7. We extrapolate that HCV eradication could occur in these participants by 63 days, although immune activation might persist. Single-cell longitudinal estimates of HCV clearance from liver have never been reported previously and could be applied to estimating the minimum treatment duration required for HCV infection.
引用
- Balagopal A, Smeaton LM, Quinn J, et al. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy. J Infect Dis. 2020. PMID: 32201883. doi:10.1093/infdis/jiaa126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。